Synergistic effect of muramyl peptide immunocorrection and prostaglandin-based vasoactive therapy in the treatment of purulent-inflammatory soft tissue diseases
DOI:
https://doi.org/10.12775/JEHS.2025.80.69632Keywords
purulent-inflammatory soft tissue diseases, type 2 diabetes mellitus, immunomodulation, muramyl peptides, microcirculation, prostaglandin E1, regenerative plateauAbstract
The treatment of purulent-inflammatory soft tissue diseases (PISTD) in type 2 diabetes mellitus (T2DM) patients remains a challenge due to the "regenerative plateau" phenomenon.
The Purpose of the Study is to improve surgical treatment efficiency in PISTD and T2DM patients by implementing a synergistic strategy based on muramyl peptide-derived immunomodulators and prostaglandin E1 analogues to restore microcirculation and activate the macrophage-neutrophil link.
Methods. A clinical study involved 148 patients (control group n=72, standard care; main group n=76, muramyl peptides + prostaglandin E1). Morphometric and immunocytochemical analyses were performed.
Results. The proposed therapy eliminated capillary sludge within 2–3 days. Myeloperoxidase (MPO) activity recovered to 72.0±6.1%. Computer planimetry showed a 59.3% wound area reduction by day 10. The average hospital stay was shortened to 9.4±1.3 days (p ≤ 0.05). Conclusions. The combined approach effectively reboots tissue regeneration by synchronizing immune response and regional blood flow.
References
1. Armstrong. D. G.. & Lipsky. B. A. (2023). Diabetic foot ulcers and their recurrence. New England Journal of Medicine. 388(20). 1858-1867.
2. IWGDF Guidelines. (2023). Guidelines on the prevention and management of diabetic foot disease. Diabetes/Metabolism Research and Reviews.
3. Lipsky. B. A.. et al. (2020). Diagnosis and treatment of diabetic foot infections. The Lancet Diabetes & Endocrinology. 8(6). 467-478.
4. Everett. E.. & Mathioudakis. N. (2021). Update on management of diabetic foot ulcers. Annals of the New York Academy of Sciences. 1411(1). 153-165.
5. Schaper. N. C.. et al. (2024). Prevention and management of foot problems in diabetes. Nature Reviews Endocrinology. 20. 112-125.
6. Lazzarini. P. A.. et al. (2022). Global epidemiology of diabetic foot ulceration. The Lancet. 399(10335). 1541-1552.
7. Boulton. A. J. M. (2023). The diabetic foot: Grand challenge for the 21st century. Diabetes Care. 46(2). 235-247.
8. Zheliba. M. D.. & Bohachuk. M. H. (2018). Morphofunctional state of leukocytes in PISTD and T2DM. Art of Medicine. (4). 74-78.
9. Sen. C. K. (2021). Human wound and its burden: Updated 2020 estimates. Advances in Wound Care. 10(5). 281-292.
10. Game. F. L.. et al. (2023). Wound bed preparation (TIME) in diabetic foot. Journal of Wound Care. 32(Sup9). S12-S22.
11. Bohachuk. M. H. (2019). Muramyl peptide immunomodulation in soft tissue infections. Clinical Anatomy and Operative Surgery. 18(3). 21-25.
12. Uccioli. L.. et al. (2020). Diabetic foot infections: The role of prostaglandins. International Journal of Lower Extremity Wounds. 19(4). 332-340.
13. Jeffcoate. W. J.. et al. (2021). The reporting of wound healing in randomized clinical trials. The Lancet Diabetes & Endocrinology. 9. 110-118.
14. Frykberg. R. G.. & Banks. J. (2020). Challenges in the treatment of chronic wounds. Surgical Technology International. 36. 120-128.
15. Edmonds. M. E.. et al. (2024). Advanced therapies for diabetic foot ulcers. British Journal of Surgery. 111(2). 145-156.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 M. Bohachuk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 2
Number of citations: 0
